MedTrace Logo

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05961839 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

Conditions

Interventions

DRUG

SGR-2921

SGR-2921 will be administered orally.

Sponsors & Collaborators

  • Schrödinger, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Weiss, M.D. · Schrödinger, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2025-08-14
Completion
2025-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961839 on ClinicalTrials.gov